beinaglutide

Peptideexperimental

Clinical trial activity

11 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
3

Earliest trial started Nov 1, 2013 (NCT01919684)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • glp-1 analog
  • lgd-6972
  • lgd-6972

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05005741Phase 4May 1, 2021Central South University, Harbin Medical University, Henan Medical University, Shantou University
NCT05226000Phase 1Jul 7, 2020Qingdao University
NCT03987308N/AJul 1, 2019Peking University
NCT03986008Phase 3Jun 20, 2019Central South University
NCT03829891N/AAug 3, 2018Xijing Hospital
NCT03593668Phase 4Dec 30, 2017Nanjing University
NCT02851849Phase 2Sep 1, 2016Ligand Pharmaceuticals
NCT02672839Phase 1Feb 1, 2016Ligand Pharmaceuticals, Medpace, Inc.
NCT02250222Phase 1Oct 1, 2014Ligand Pharmaceuticals
NCT02227849Phase 4Aug 1, 2014Kyoto University, Mitsubishi Tanabe
NCT01919684Phase 1Nov 1, 2013Beckloff Associates, Inc., Ligand Pharmaceuticals, Medpace, Inc.
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Ligand PharmaceuticalsFor profit4422013
Central South UniversityAcademic/Hospital2222019
Medpace, Inc.For profit2012013
Beckloff Associates, Inc.For profit1012013
Harbin Medical UniversityAcademic/Hospital1012021
Henan Medical UniversityAcademic/Hospital1012021
Kyoto UniversityAcademic/Hospital1012014
Mitsubishi TanabeFor profit1112014
Nanjing UniversityAcademic/Hospital1112017
Peking UniversityAcademic/Hospital1112019
Qingdao UniversityAcademic/Hospital1112020
Shantou UniversityAcademic/Hospital1012021
Xijing HospitalAcademic/Hospital1112018
13 organizations
Page 1 / 1